Urelumab (anti-TNFRSF9) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF9, >95%, high purity, Human IgG4SP, Antibody of 4-1BB
Urelumab (anti-TNFRSF9) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF9, >95%, high purity, Human IgG4SP, Antibody of 4-1BB
Urelumab (anti-TNFRSF9) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF9, >95%, high purity, Human IgG4SP
Urelumab is a humanized IgG4 monoclonal antibody used as a CD137 agonist to enhance the antitumor activity of T cells and natural killer cells, and to enhance the cytotoxic activity of Rituximab. Urelumab can be used in studies of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL). Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Antibody Type
Primary antibody
Clonality
Recombinant
Isotype
Human IgG4SP
Light Chain Type
kappa
SDS-PAGE
26.9 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 180.9 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Purity
>95%
Source
CHO supernatant
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
934823-49-1
Images
Urelumab (anti-TNFRSF9) (Ab170654) - ELISA Immobilized N-His-HSA-TNFSF9/4-1BB-ECD at 2 μg/mL can bind Urelumab (anti-TNFRSF9) (Ab170654) with the EC50 of 12.68 ng/mL.
Urelumab (anti-TNFRSF9) (Ab170654) - SEC The purity of Urelumab (anti-TNFRSF9) (Ab170654) is more than 95% verified by HPLC.
Associated Targets(Human)
TNFRSF9TbioTumor necrosis factor receptor superfamily member 9 (0 Activities)
1.Molckovsky A, Siu LL. (2008) First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.. J Hematol Oncol, 1 (3):(20). [PMID:18959794]
2.Li SY, Liu Y. (2013) Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137.. Clin Pharmacol, 5 (Suppl 1):(47-53). [PMID:24052693]
3.Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M et al.. (2016) Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.. Eur J Immunol, 46 (3):(513-22). [PMID:26773716]
4.Zhou, Z Z and 6 more authors.. (1995) Characterization of human homologue of 4-1BB and its ligand.. Immunology letters, [PMID:7622190]
5.Alderson, M R MR and 9 more authors.. (1994) Molecular and biological characterization of human 4-1BB and its ligand.. European journal of immunology, [PMID:8088337]
6.Schwarz, H H, Tuckwell, J J and Lotz, M M.. (1993) A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family.. Gene, (8):[PMID:8262389]
7.Jang, L K LK and 5 more authors.. (2001) A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction.. Molecules and cells, (31):[PMID:11804328]
8.Saoulli, K K and 10 more authors.. (1998) CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.. The Journal of experimental medicine, (1):[PMID:9607925]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
ZJ24F0303034